394  Pharmaceutical  Products  in  France.  {AmjJne%9igarm" 
The  pre-war  attitude  of  the  French  manufacturer  was  that  if 
the  German  product  had  a  small  sale  he  left  it  alone.  If,  on  the 
contrary,  the  sale  developed  the  French  manufacturer  produced  a 
preparation  of  the  same  chemical  composition  and  put  it  on  sale 
either  under  its  chemical  name  or  under  another  name  chosen  by 
himself.  In  every  case  the  use  of  the  German  trade-mark  was 
denied  him  as  constituting  an  international  industrial  property. 
This  explains  why  before  the  war  only  such  products  which  could 
by  their  popularity  justify  the  expense  and  risk  of  their  production 
were  manufactured  in  France. 
Among  the  more  important  of  the  organic  or  mineral  products 
sold  under  a  German  mark  were :  Adalin,  ansesthesin,  antipyrine, 
aristol,  aspirin,  atophan,  bismon,  bornyval,  bromipin,  bromural,  ci- 
trophen,  collargol,  creosotal,  dermatol,  dionin,  diuretin,  euquinine, 
helmitol,  heroin,  lactophenin,  luminal,  lycetol,  lysol,  salvarsan  and 
neosalvarsan,  novocain,  orthoform,  phenacetin,  protargol,  pyrami- 
don,  salophen,  somatose,  sulphonal,  trional,  urotropin,  veronal,  xero- 
form.  Of  these  all  except  anaesthesin,  atophan,  bismon,  bornyval, 
citrophen,  phenacetin,  salophen,  somatose,  sulphonal  and  trional,  are 
now  made  in  France. 
In  suppressing  German  competition,  the  war  has  made  it  com- 
paratively easy  to  launch  on  the  market,  under  a  new  trade-mark 
name,  certain  of  these  products  which  are  still  in  demand  among 
medical  men.  On  the  other  hand,  some  French  manufacturers  be- 
fore the  war  were  able  to  secure  by  judicial  action  that  certain 
marks  which  had  become  the  usual  name  of  the  product  (for  in- 
stance, antipyrine,  pyramidon,  etc.)  should  be  put  into  general  use. 
Two  ways  are  open  to  French  manufacturers :  either  they  can 
reproduce  chemically  the  German  products  and  face  the  competition, 
or  they  may  build  up  new  compounds  of  proved  therapeutic  prop- 
erties and  place  them  before  the  medical  profession.  The  diffi- 
culties of  the  task  must  not  be  overlooked.  Well-equipped  labora- 
tories are  necessary,  manned  by  chemists  trained  to  research,  par- 
ticularly in  organic  chemistry,  and,  above  all,  the  possibilities  of 
physiological  experiment  must  be  attended  to.  On  the  other  hand, 
the  industry  in  pharmaceutical  products  sold  under  a  trade-mark 
requires  usually  but  a  small,  though  perfect,  plant,  and  there  is  less 
risk  of  such  trade  being  submerged  by  the  dye  and  synthetic  per- 
fume industries. 
M.  Detoeuf's  illuminating  review  of  the  situation  shows  quite 
